UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 223

Sortiert nach

Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)

International journal of oncology, 2014-11, Vol.45 (5), p.1793-1801

2014

Volltextzugriff (PDF)

Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.59-69

2015

Volltextzugriff (PDF)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

PloS one, 2016-04, Vol.11 (4), p.e0152861

2016

Volltextzugriff (PDF)

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Journal of clinical oncology, 2015-04, Vol.33 (10), p.1151-1156

2015

Volltextzugriff (PDF)

The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites

Drug metabolism and disposition, 2020-11, Vol.48 (11), p.1113-1120

2020

Volltextzugriff (PDF)

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients

The Prostate, 2019-11, Vol.79 (15), p.1767-1776

2019

Volltextzugriff (PDF)

EDITORIAL COMMENT

Urology (Ridgewood, N.J.), 2020-04, Vol.138, p.97

Toren, Paul

2020

Volltextzugriff (PDF)

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs

Scientific reports, 2021-09, Vol.11 (1), p.19299-19299, Article 19299

2021

Volltextzugriff (PDF)

High infiltration of CD209 + dendritic cells and CD163 + macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes

Frontiers in immunology, 2023-06, Vol.14, p.1205266-1205266

2023

Volltextzugriff (PDF)

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

Drug metabolism and disposition, 2006-01, Vol.34 (1), p.191

2006

Volltextzugriff (PDF)

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

Clinical and translational science, 2024-04, Vol.17 (4), p.e13782-n/a

2024

Volltextzugriff (PDF)

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

Nutrients, 2023-03, Vol.15 (6), p.1369

2023

Volltextzugriff (PDF)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment

European urology open science (Online), 2022-09, Vol.43, p.35-44

2022

Volltextzugriff (PDF)

Small Incidentally Discovered Testicular Masses in Infertile Men—Is Active Surveillance the New Standard of Care?

The Journal of urology, 2010-04, Vol.183 (4), p.1373-1377

2010

Volltextzugriff (PDF)

Sex steroids in the tumor microenvironment and prostate cancer progression

Endocrine-related cancer, 2018-03, Vol.25 (3), p.R179-R196

2018

Volltextzugriff (PDF)

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

Asian journal of andrology, 2022-01, Vol.24 (1), p.21-25

2022

Volltextzugriff (PDF)

Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial

Cancer medicine (Malden, MA), 2023-10, Vol.12 (19), p.20163-20176

2023

Volltextzugriff (PDF)

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes

Drug metabolism and disposition, 2011-08, Vol.39 (8), p.1370

2011

Volltextzugriff (PDF)

How do androgens affect prostate cancer extracellular vesicles?

ExRNA, 2022-01, Vol.4, p.1-1

Toren, Paul

2022

Volltextzugriff (PDF)

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype

Clinical and translational medicine, 2022-01, Vol.12 (1), p.e581-n/a

2022

Volltextzugriff (PDF)

High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling

Drug metabolism and disposition, 2012-10, Vol.40 (10), p.1966

2012

Volltextzugriff (PDF)

A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

Communications medicine, 2024-03, Vol.4 (1), p.56-56, Article 56

2024

Volltextzugriff (PDF)

EDITORIAL COMMENT

Urology (Ridgewood, N.J.), 2020-04, Vol.138, p.97-97

Toren, Paul

2020

Volltextzugriff (PDF)

EDITORIAL COMMENT

Urology (Ridgewood, N.J.), 2020-04, Vol.138, p.97

Toren, Paul

2020

Volltextzugriff (PDF)

Tyr1‑ψ[(Z)CFCH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin

ACS chemical neuroscience, 2018-07, Vol.9 (7), p.1735-1742

2018

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(132)
Humans
(98)
Male
(69)
Adult
(41)
Urology & Nephrology
(41)
Female
(40)
Biological And Medical Sciences
(34)
Middle Aged
(31)
Medical Sciences
(30)
Risk Factors
(29)
Prostate Cancer
(28)
Asthma
(26)
Respiratory System
(24)
General & Internal Medicine
(21)
Occupational Exposure - Adverse Effects
(21)
Oncology
(20)
Aged
(18)
Asthma - Epidemiology
(18)
Urology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)

Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients

EDITORIAL COMMENT

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs

High infiltration of CD209 + dendritic cells and CD163 + macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment

Small Incidentally Discovered Testicular Masses in Infertile Men—Is Active Surveillance the New Standard of Care?

Sex steroids in the tumor microenvironment and prostate cancer progression

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes

How do androgens affect prostate cancer extracellular vesicles?

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype

High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling

A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

EDITORIAL COMMENT

EDITORIAL COMMENT

Tyr1‑ψ[(Z)CFCH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin

Suchergebnisse filtern